Stock LIXT LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Lixte Biotechnology Holdings, Inc.

Equities

LIXT

US5393193017

Market Closed - Nasdaq
Other stock markets
 21:30:01 28/06/2024 BST 		5-day change 1st Jan Change
2.37 USD 0.00% Intraday chart for Lixte Biotechnology Holdings, Inc. -6.69% +0.85%
06-14 Lixte Biotechnology Holdings, Inc. to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial CI
06-06 Lixte Biotechnology Holdings, Inc. Reports Findings Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
AQ
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial
AQ
Lixte Biotechnology Holdings, Inc. to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial
CI
Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System
AQ
Lixte Biotechnology Holdings, Inc. Reports Findings Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System
CI
LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer
AQ
LIXTE Biotechnology Holdings, Inc. Announces Executive Changes
CI
LIXTE Biotechnology Holdings Provides Update on Recent Activities
AQ
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
AQ
Lixte Biotechnology : Investor Presentation - April 2024
PU
Lixte Biotechnology Files Up to $50 Million Mixed Shelf
MT
Sector Update: Health Care Stocks Advance Late Afternoon
MT
Top Midday Gainers
MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data
MT
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
AQ
Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal
CI
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
AQ
LIXTE Biotechnology Holdings, Inc. Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
CI
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LIXT Stock
  4. News Lixte Biotechnology Holdings, Inc.